Price Controls: The Wrong Rx
The 65 interest groups testifying on Mar. 29 at the marathon hearing of the White House health-care-reform task force offered a confusing babble of conflicting ideas. But the message radiating from the members of the task force was loud and clear. From one end of the dais to the other, Clintonites signed on to price controls as a necessary step in stopping the double-digit inflation of medical costs. Even Robert E. Rubin, who as head of the National Economic Council should know better, suggested that maybe, just maybe, this time controls would work and not fuel a price surge in the long run.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Bitcoin Futures Deliver Wild Ride as Debut Brings Rally, Halts
- Investors Told to Brace for Steepest Rate Hikes Since 2006
- Longtime NPR Host Tom Ashbrook Is Facing Misconduct Allegations
- Times Square Subway Bomber Tells Police He’s a Follower of Islamic State
- Buffett's About to Get $3 Billion Back From Burger King Owner